Practice Update: Updated Results of Belzutifan for Advanced RCC

Cohort 1 LITESPARK-003: belzutifan + cabozantinib 1L treatment for advanced RCCПодробнее

Belzutifan for VHL Disease-Associated Renal Cell CarcinomaПодробнее

Updated Results of a Trial of MK-6482 for Patients With Advanced Clear Cell RCCПодробнее

Longer Term Outcomes With Pembrolizumab Plus Axitinib for Advanced RCCПодробнее

Practice Update: Belzutifan FDA Approval for VHL-Associated CancersПодробнее

Highlights on belzutifan in previously treated advanced clear cell RCC: The LITESPARK-005 studyПодробнее

RCC Update from ESMO 2023Подробнее

Kidney Cancer Conference Highlights from ASCO 2022Подробнее

Updated Results of a Clinical Trial Evaluating Pembrolizumab + Axitinib for Frontline Adv RCCПодробнее

Cabozantinib as Immune Modulatory Therapy for Advanced RCCПодробнее

Dosing and Combinations of Sunitinib vis-à-vis Alternative Therapies for RCCПодробнее

Nivolumab Plus Cabozantinib for Patients With Advanced RCC With Sarcomatoid HistologyПодробнее

LITESPARK-004: 36 month follow-up of belzutifan in Von Hippel-Lindau syndromeПодробнее

Dr. Laurence Albiges on Results of Arm B5 of KEYMAKER-U03B for Belzutifan Plus Lenvatinib in accRCCПодробнее

Belzutifan real-world vs clinical trial data: comparing efficacy and safety in VHL-associated tumorsПодробнее

Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCCПодробнее

David A. Braun, MD, PhD, discusses the preliminary analysis of belzutifan + cabozantinib in ccRCCПодробнее

Novel HIF-2a Inhibitor for Patients With Advanced Renal Cell CarcinomaПодробнее

Kidney Cancer Highlights from ESMO 2022Подробнее